https://www.selleckchem.com/pr....oducts/avelestat-azd
Background The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. The optimal pneumococcal vaccination strategy for SOT patients is not known. Methods The potential kidney transplant recipients in dialysis were randomized into two arms to receive a 23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13) before transplantation and a second dose of PCV13 six months after the transplantation. Sero
Like
Comment
Share
